Form 8-K ARIAD PHARMACEUTICALS For: Aug 06
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/24/2026
- Wall Street ends down as oil prices, Treasury yields rise
- BTIG’s Krinsky warns 2000-like signals are mounting
- HSBC remains max bullish on stocks, tells investors to lean into tech
- Analyst explains why the midterm outcome is a “fundamental non-event”
- Oil settles up around 4% as Iran's president vows to never surrender
- Wall Street ends down as oil prices, Treasury yields rise
- Anthropic's Claude AI identifies novel enzyme system in DNA search
- AppLovin (APP) on watch amid 3% drop premarket as boutique comments circulate
- Plug Power COO resigns to join another company
- Xtend AI Robotics wins Phase III of USSOCOM lethal drone program
Chardan Affirms ARIAD (ARIA) at 'Buy'; Narrower Label Impacts Iclusig Usage
August 7, 2014 10:26 AM EDTChardan Capital affirms ARIAD Pharma (Nasdaq: ARIA) at Buy with a $9 price target following Q2 results.
ARIAD posted Q2 revs of $12.1 million and loss of $0.30 per share, with Chardan at revs of $11.6 million and loss of $0.30 per share.
Analyst Ling Wang noted the following key points from the quarter:Iclusig is being used in later lines of patients impacted by a narrower label. Through 2Q14, ~550 patients in the U.S. received Iclusig in the commercial setting (with a weekly penetration of over 50%)... More
